Responses
Clinical and epidemiological research
Extended report
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
Compose a Response to This Article
Other responses
No responses have been published for this article.